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Abstract  
Background and objectives 
Intensified immunosuppression in steroid resistant nephrotic syndrome is broadly applied, 
with disparate outcomes. This review of patients from the UK NephroS cohort aimed to 
improve disease stratification by determining, in comprehensively genetically-screened 
steroid resistant nephrotic syndrome patients, if there is an association between response to 
initial intensified immunosuppression and disease progression and/or post-transplant 
recurrence.  
 
Design, setting, participants, and measurements 
Paediatric steroid resistant nephrotic syndrome patients were recruited via the UK RaDaR 
registry. All patients were whole genome, whole exome or steroid resistant nephrotic 
syndrome-gene-panel sequenced. Complete response or partial response within six months 
of starting intensified immunosuppression was ascertained using laboratory data. Response 
to intensified immunosuppression and outcomes were analysed according to genetic testing 
results, pattern of steroid resistance and first biopsy findings.  
 
Results 
Of 271 patients, 178 (92 male, median onset age 4.7 years) received intensified 
immunosuppression with response available. 4% of monogenic disease patients showed 
complete response, compared to 25% of genetic-testing negative patients (p=0.02). None of 
the former recurred post-transplantation. In genetic-testing negative patients, 97% with 
complete response to first intensified immunosuppression did not progress whereas 44% of 
non-responders developed kidney failure with 73% recurrence post-transplant. Secondary 
steroid resistance had a higher complete response rate than primary/presumed resistance 
(43% vs 23%, p=0.001). Highest complete response rate in secondary steroid resistance 
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was to Rituximab (64%). Biopsy results showed no correlation with intensified 
immunosuppression response or outcome.  
 
Conclusions 
Patients with monogenic steroid resistant nephrotic syndrome had a poor therapeutic 
response and no post-transplant recurrence. In genetic-testing negative patients, there was 
a clear association between response to first intensified immunosuppression and long-term 
outcome. Patients with complete response rarely progressed to kidney failure, whereas non-
responders had poor kidney survival and a high post-transplant recurrence rate. Patients 
with secondary steroid resistance were more likely to respond, particularly to Rituximab.   
 
Introduction 
Approximately 10-15% of children with nephrotic syndrome are resistant to steroids,(1, 2) 
and most of these receive intensified (or second-line) immunosuppression. Response is 
often disappointing and there are significant side effects. 30-40% progress to kidney failure 
within 10 years, requiring dialysis and transplantation.(3) Disease recurrence is common and 
associated with poor long-term outcome. Unfortunately, our ability to predict the disease 
course, treatment response and risk of post-transplantation recurrence for individual patients 
is limited.  
 
There are many proposed risk factors for post-transplantation recurrence including age at 
diagnosis, rate of progression to kidney failure, biopsy result, ethnicity and previous 
recurrence.(4, 5) However, the most informative factors remain secondary steroid resistance 
for increased risk,(6) or a monogenic cause of disease as a protective feature. Mutations 
have been identified in over 70 genes, causing podocyte defects, and are responsible for 
approximately 30% of childhood steroid resistant nephrotic syndrome.(7-21) Patients with 
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genetic disease are usually resistant to immunosuppression and progress more rapidly to 
kidney failure but do not recur after transplantation.(7, 22)  
 
Post-transplantation recurrence is thought to be immune-mediated. It is hypothesised that a 
plasma circulating factor, derived from immune cell dysfunction, acts on the podocyte and 
disrupts glomerular permeability. However, its identity remains elusive.(23-25) . We have 
previously shown that secondary steroid resistance can be used as a marker for circulating 
factor disease and is associated with a high risk of post-transplantation recurrence.(6) 
Strikingly, 93% of patients with secondary steroid resistance recurred post-transplantation 
compared to 30% with primary steroid resistance.  
 
The latter study lacked detailed genetic analyses. We propose that comprehensively 
genetically-stratifying steroid resistant nephrotic syndrome patients, then correlating 
response to intensified immunosuppression with progression to kidney failure and 
recurrence, will identify subgroups which are useful for clinical prognostication and 
management.  Our results identify two distinct groups of genetic-testing negative patients: 
one that responds to intensified immunosuppression and has a good long-term outcome, 
and one that is multi-drug resistant with rapid progression, very poor kidney survival and 
high post-transplant recurrence risk. 
 
Materials and Methods 
Patient Cohort 
Cases were taken from the UK Renal Rare Disease Registry (RaDaR), a Renal Association 
initiative set up in 2010 which collates clinical data from patients with rare kidney 
diseases.(26) Data are collected both retrospectively and prospectively via an online portal 
and include demographics, family history, consanguinity, pattern of steroid resistance, 
medications, transplantation and recurrence. Cases were selected in January 2018, at which 
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point there were 2457 patients with idiopathic nephrotic syndrome enrolled (see 
supplemental material for inclusion/exclusion criteria). Patients included in this analysis had 
steroid resistant nephrotic syndrome with age of onset <18 years and were screened for 
disease causing mutations. Steroid resistant nephrotic syndrome is defined as failure to 
respond to four weeks of high-dose oral prednisolone. The cohort consisted of 271 patients 
(Figure 1) with a date of diagnosis ranging from 1995 to 2017. 188 patients had whole 
exome sequencing,(7) 9 whole genome sequencing, and 74 clinical gene panel testing. 68 
clinical gene panel testing patients underwent testing at Bristol Genetics Laboratory with 
next generation sequencing of 37 (27) or 70 genes associated with steroid resistant 
nephrotic syndrome.(28) The remaining six clinical gene panel testing patients had testing in 
other locations, with results documented in RaDaR. Patients were considered to have 
monogenic disease if a mutation was found in one of the known ‘nephrotic’ genes.(7, 27) 
Follow-up data were inputted to the RaDaR registry on at least a six monthly basis. Local 
clinical teams were contacted individually to provide specific items of missing data. 
 
Clinical Data Retrieval 
Demographic, clinical and long-term outcome data were extracted from the RaDaR 
database. Only medications started prior to kidney failure, and only the first course of each 
medication, were included. Complete response was defined as urine protein:creatinine ratio 
(UPCR) <200mg/g, urine albumin:creatinine ratio (UACR) <30mg/g or negative/trace dipstick 
proteinuria within six months of starting therapy. Partial response was defined as UPCR 
>200mg/g or dipstick ≥1+ but plasma albumin >2.5g/dL. If a medication was stopped within 
six months, only laboratory data while receiving the medication were used. If two 
medications were started simultaneously or within one month, the same response outcome 
was assigned to both. For management of missing data, see supplemental material. 
 
Data Analysis 
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Proportions of patients achieving complete and partial response were calculated for the 
whole cohort and stratified by genetic disease, pattern of steroid resistance and biopsy 
results. Particular attention was given to genetic-testing negative patients with post-
transplant recurrence as they are most likely to have circulating factor disease. To minimise 
bias from the order in which clinicians chose to use medications, outcomes for the first 
intensified immunosuppression drug used per patient were analysed separately.   
 
Statistical Analysis 
Data analysis was performed using GraphPad Prism 7 with Fisher’s exact test, Chi-squared 
analysis or Mann-Whitney U test.    
 
Results 
Patient Characteristics 
Demographic features of the 271 patients and the treatments received are shown in Tables 
1 and 2. In total, 186 patients (69%) received intensified immunosuppression. Completeness 
of response data was 91%. 346 intensified immunosuppression treatments with responses 
available were given to 178 patients.  
 
Response and Outcomes in Patients with Monogenic Disease 
Of the 271 patients, 81 (30%) had monogenic disease. 26 (32%) of these were treated with 
intensified immunosuppression. Complete response to first intensified immunosuppression 
was seen in 4% of monogenic patients compared to 25% of genetic-testing negative patients 
(p=0.02; no data n=0/26 monogenic, n=3/152 genetic-testing negative patients). There was 
a significant difference in combined complete and partial response between monogenic and 
genetic-testing negative patients for all intensified immunosuppression treatments (35% vs 
53%, p=0.04; no data n=5/45 monogenic, n=29/335 genetic-testing negative treatment 
episodes) but not for first intensified immunosuppression only (35% vs 46%, p=0.29). One 
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monogenic patient had complete response and eight showed partial response to first-
administered intensified immunosuppression (Table 3). None of the 21 monogenic patients 
(26%) who received a transplant had responded to intensified immunosuppression and none 
recurred post-transplantation. This is significantly different to transplanted genetic-testing 
negative patients who had a 68% recurrence rate (21/31) post-transplantation. 
 
Response to Immunosuppression in Genetic-testing Negative Patients 
Of the 190 genetic-testing negative patients, 152 received 306 intensified 
immunosuppression treatments with response data available (no data n=29/335 treatment 
episodes). The average number of treatments was two per patient (range one to five). 
Overall, the complete response rate was 28%. Complete response was highest for 
Rituximab (39%, 16/41; no data n=1) and lowest for cyclophosphamide (19%, 8/43; no data 
n=5) but this was not statistically significant (p=0.05).  The combined complete and partial 
response rate was highest for tacrolimus (59%, 48/82; no data n=4) and this was significant 
compared to cyclophosphamide (40%, p=0.04, Figure 2a). Response data were available for 
first-administered intensified immunosuppression in 149 patients (no data n=3). Ciclosporin 
was the first treatment in 66 patients (44%), tacrolimus in 35 (23%) and cyclophosphamide 
in 32 (21%). Ciclosporin and tacrolimus had similar levels of complete response (27% and 
31% respectively, Figure 2b). This was higher than cyclophosphamide (13%) but not 
statistically significant (p=0.13 vs ciclosporin, p=0.08 vs tacrolimus).  
 
Association between Response to First Intensified Immunosuppression and 
Likelihood of Kidney Failure in Genetic-testing Negative patients 
Characteristics and long-term outcomes for genetic-testing negative patients stratified by 
response to first intensified immunosuppression treatment are shown in Table 4. The 
median follow-up time was 5.2 years (range 0.1-22.2 years). Strikingly 97% of patients 
(36/37) with complete response showed no progression to kidney failure (median follow-up 
5.0 years, range 0.1-15.2 years) (Figure 3). Non-responders had significantly quicker 
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progression to kidney failure as shown in the Kaplan-Meier survival curves (p<0.001, Mantel-
Cox test) (Figure 2c).  The five-year kidney failure-free survival rates were 97%, 87% and 
59% for patients with complete, partial and no response respectively.  The corresponding 
10-year rates were 97%, 74% and 27%. Frequency of transplantation was significantly 
higher in non-responders (p<0.001). In total, 31 genetic-testing negative patients received a 
transplant. 26 (84%) were non-responders to first intensified immunosuppression, four had 
partial response and only one complete response. The overall recurrence rate was 68% 
(21/31) with 73% (19/26) recurrence in non-responders. Strikingly, kidney survival for 
genetic-testing negative patients with no response to first intensified immunosuppression is 
the same as for patients with monogenic disease (Figure 2c). This supersedes previous data 
where comparison between monogenic and (all) non-monogenic steroid resistant nephrotic 
syndrome shows worse kidney survival for monogenic patients.(2, 7) 
 
Response Stratified by Pattern of Steroid Resistance  
Genetic-testing negative patients with primary steroid resistance (120 patients) were 
analysed as a distinct subgroup from secondary steroid resistance (32 patients). Secondary 
steroid resistant patients had significantly higher complete response than those with genetic-
testing negative primary steroid resistance (43% vs 23%, p=0.001; no data n=29/334 
treatment episodes). The combined complete and partial response rate was also 
significantly higher (65% vs 48%, p=0.01). The highest complete response rate was to 
Rituximab with 64% (9/14, no data n=1) in secondary steroid resistant patients compared to 
26% (7/27) in genetic-testing negative primary steroid resistance (p=0.02). Secondary 
steroid resistant patients also had a significantly higher complete response rate to 
cyclophosphamide (38% vs 10%, p=0.04; no data n=3/16 secondary steroid resistant, 
n=2/32 primary steroid resistant patients). When considering only first intensified 
immunosuppression, there was no significant difference in response between the two groups 
(complete response 36% vs 22%, p=0.16; combined complete and partial response 61% vs 
42%, p=0.07; no data n=3/152). 22% of genetic-testing negative primary steroid resistant 
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patients received a transplant, with 69% (18/26) recurrence rate. 16% of secondary steroid 
resistant patients were transplanted with 60% (3/5) recurrence rate.  
 
Characteristics and Outcomes in Patients Treated with Rituximab 
Complete response to intensified immunosuppression was generally below 30%. The 
exception was Rituximab in patients with secondary steroid resistance (64%) so these 
patients have been analysed in more detail (Figure 4). In total, 46 patients received 
Rituximab. Treatment was performed according to centre-based decisions. Six were 
simultaneously treated with other intensified immunosuppression (one mycophenolate 
mofetil, one ciclosporin, three tacrolimus, one with both tacrolimus and mycophenolate 
mofetil). These six patients all had primary steroid resistance and showed a varied response 
(one complete, three partial and two non-responders). Four monogenic patients received 
Rituximab, and none responded. 42 genetic-testing negative patients were given Rituximab 
(no data n=1). Complete response was 39% (16/41) and partial response 12% (5/41); not 
statistically significant compared to other medications. No complete responders progressed 
to kidney failure (0/16, median follow-up 7.6 years). 50% (10/20) of non-responders 
developed kidney failure (median follow-up 5.4 years) with an 83% (5/6) post-transplant 
recurrence rate. There was no significant difference between responders and non-
responders in terms of median age of diagnosis or time between diagnosis and treatment. 
15 secondary steroid resistant patients received Rituximab (no data n=1). Complete 
response occurred in 64% (9/14) and none of these developed kidney failure (median follow-
up 7.2 years). Of the four non-responders, two developed kidney failure and both recurred 
following transplantation. 27 genetic-testing negative primary steroid resistant patients 
received Rituximab. Complete response occurred in 26% (significantly lower than in 
secondary steroid resistant patients, p=0.02) and no response in 59%. 50% of non-
responders developed kidney failure and three out of the four transplanted patients suffered 
recurrence.   
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To validate these findings, we examined the comprehensive database of Necker Hospital, 
Paris, for outcomes of paediatric steroid resistant nephrotic syndrome patients treated with 
Rituximab.(29) In 82 genetic-testing negative primary steroid resistant patients with no 
response to first intensified immunosuppression treatment, 60/82 (73%) showed no 
response to Rituximab. 29/60 (48%) of these developed kidney failure and 8/17 (47%) who 
were transplanted suffered disease recurrence. None of the 22 patients with complete (10) 
or partial response (12) progressed to kidney failure. No patients with secondary steroid 
resistance were treated with Rituximab. 
 
Response Stratified by First Biopsy Findings 
170 patients receiving intensified immunosuppression had biopsy results available (not 
biopsied/no data n=16). Focal segmental glomerulosclerosis (FSGS) was seen in 100 (59%) 
first biopsies, minimal change disease (MCD) in 45 (26%) and mesangial hypercellularity in 
11 (6%). Other findings are detailed in supplemental material (Table S2).  There was no 
significant difference in response to intensified immunosuppression or clinical outcome 
based on biopsy findings. When considering only FSGS and MCD, there was no significant 
difference in complete response (24% vs 27%, p=0.66) or in combined complete and partial 
response (49% vs 51%, p=0.70; no data n=27/300 treatment episodes). 
 
Discussion 
Our ability to predict long-term outcome and risk of post-transplantation recurrence in 
paediatric steroid resistant nephrotic syndrome is limited. There is now emerging literature 
regarding the differences between responders and non-responders to intensified 
immunosuppression.(1, 2) However, these studies lack comprehensive genetic stratification 
and their clinical message has not yet been widely appreciated. We present data from a 
large, national cohort of paediatric steroid resistant nephrotic syndrome patients with an 
emphasis on full genetic screening. This allows us to reinforce and validate the findings of 
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recent literature regarding response to intensified immunosuppression, and also adds 
substantial new information regarding clinical outcomes, individual therapies, biopsy findings 
and post-transplantation recurrence.  
 
We focused our stratification on complete versus no response, as partial response is more 
susceptible to natural variation, incomplete recording, and confounding by haemodynamic 
factors (e.g. ACE inhibition). Nevertheless, it is interesting that most partial responders had 
good outcomes, suggesting they are in the same or similar immune mechanistic category as 
complete responders. We defined complete response as occurring within six months of 
starting treatment. To a certain extent, this is arbitrary and may underestimate later 
responders. One German study of 231 steroid resistant nephrotic syndrome patients 
reported 60% complete response to ciclosporin A in genetic-testing negative patients, with 
18% of those achieving complete response doing so beyond six months.(30) However, the 
response rate in this cohort remains high even when late responders are accounted for; 
approximately 49% showed complete response within six months compared to 28% in our 
study. Our findings are very similar to that shown by the largest steroid resistant nephrotic 
syndrome cohort to date, where complete response to calcineurin inhibitors was 29.9%, and 
fits within the wider literature.(2, 31-33) We believe the six month period will capture the 
majority of responders whilst minimising the potential for confounding.  
 
Our results confirm that monogenic disease is a distinct subgroup which responds very 
poorly to immunosuppression. There is no convincing evidence of complete response to 
intensified immunosuppression in monogenic disease, albeit several reported cases.(22, 30, 
34) Here, one monogenic patient (out of 26) demonstrated complete response. This patient 
has a WT1 mutation, with Denys-Drash Syndrome. Case reports suggest response to 
immunosuppression, usually cyclosporin A, in WT1-associated nephrotic syndrome.(35-37) 
Therefore, in this specific mutation, we cannot rule out a direct effect of intensified 
immunosuppression on podocytes. None of the 21 transplanted monogenic patients suffered 
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post-transplantation recurrence, compared to 68% (21/31) of genetic-testing negative 
patients. This is consistent with previous literature reporting that monogenic patients do not 
generally recur after transplantation. Patients were considered to have monogenic disease 
only if a mutation was found in a known ‘nephrotic’ gene, regardless of family history. Of the 
genetic-testing negative patients who received intensified immunosuppression, seven had 
an affected first-degree relative. One had presumed steroid resistance, family consanguinity 
(no family history) and a variant of unknown significance in WT1.(7) It is possible that some 
of these patients may have monogenic disease due to currently undiscovered gene 
mutations.  
 
The genetic-testing negative subgroup is more heterogenous making it harder to predict 
treatment response and outcome. There was no significant difference in response or clinical 
outcome based on first biopsy finding, suggesting this is a poor discriminator. However, 
there was a clear association between response to first intensified immunosuppression and 
long-term outcome: responders (complete and partial) rarely developed kidney failure, 
whereas non-responders had a high likelihood of kidney failure and post-transplantation 
recurrence.  
 
These results are generally consistent with those published from the PodoNet registry, 
where 27% of non-genetic patients responded completely to intensified immunosuppression, 
though only 43% of the cohort had gene panel sequencing, and correlation between 
intensified immunosuppression and post-transplant recurrence was not performed (1, 2). 
Our study only included patients with comprehensive genetic screening, thereby reflecting 
current clinical practice. 97% of patients with complete response did not develop kidney 
failure and the ten-year kidney failure-free survival rate was 97%. The one patient with 
complete response who developed kidney failure was steroid sensitive at initial treatment 
(secondary steroid resistance), and treated with ciclosporin. They suffered post-transplant 
recurrence. In contrast, 44% of non-responders to first intensified immunosuppression 
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progressed to kidney failure (ten-year kidney failure-free survival 28%) and the post-
transplantation recurrence rate was 73%. One advantage of thorough stratification is that we 
show the time to kidney failure in the non-responders is as rapid as the monogenic group 
(Figure 2c). This is in contrast to the previous less stratified studies by ourselves and 
Trautmann et al, where monogenic patients more rapid progression than non-monogenic 
patients.(2, 7) 
 
We have previously shown that secondary steroid resistance is associated with post-
transplantation recurrence. In this study, there was no difference in recurrence between 
secondary steroid resistance and genetic-testing negative primary steroid resistance, but the 
numbers are too small to be conclusive. The most striking difference was the response to 
Rituximab. 64% of secondary steroid resistant patients showed complete response, 
compared to 26% (12% Paris cohort) in genetic-testing negative primary steroid resistance 
(p=0.02). No patients with complete response to Rituximab progressed to kidney failure 
(0/16 United Kingdom (UK) cohort; 0/10 Paris). The number of Rituxumab treated secondary 
steroid resistant patients is currently small but it raises an interesting new observation that 
should be explored further as the numbers in these cohorts increase. The clinical implication 
in our view is that all genetic-testing negative patients resistant to their first intensified 
immunosuppression should be treated with Rituximab, as a proportion (26% of genetic-
testing negative primary steroid resistance, 64% of secondary steroid resistance) will 
respond and not progress. This is also consistent with currently 11 published observational 
studies and one randomised controlled trial for multidrug resistant steroid resistant nephrotic 
syndrome, where in total approximately 30% of almost 200 treated patients achieved 
complete remission.(38-49)  
 
Some medications in secondary steroid resistant patients may have commenced whilst they 
were still steroid sensitive or already in remission. Our response criteria do not distinguish 
these patients, and this could contribute to the high response rate to Rituximab in the 
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secondary steroid resistance group. Of the 14 secondary steroid resistant patients receiving 
Rituximab (with response data available), five were steroid resistant when starting treatment, 
four steroid sensitive and five unknown. Complete response occurred in all steroid sensitive 
patients and three of the five resistant patients. None of the steroid sensitive patients 
progressed to kidney failure (median follow-up 8.2 years).  
 
In summary, we have identified three subgroups of steroid resistant nephrotic syndrome 
which likely represent mechanistically different disease (Figure 3). Firstly, patients with 
monogenic disease show poor or no response to immunosuppression and generally do not 
recur after transplantation. Secondly, genetic-testing negative patients who respond to first 
intensified immunosuppression rarely progress to kidney failure. Thirdly, those who fail first 
intensified immunosuppression usually become multi-drug resistant with high likelihood of 
rapid progression to kidney failure and 73% risk of post-transplantation recurrence. These 
patients mostly have immune-mediated circulating factor disease, given the very high rate of 
post-transplant recurrence. A smaller proportion will be monogenic with currently-
undiscovered gene mutations. Response to Rituximab identifies a subset of patients whose 
disease may be B cell mediated, although the drug could also have a direct action on 
podocytes.(50) Response is high in secondary steroid resistant patients and associated with 
good long-term outcome. 
 
We propose that stratification according to genetic testing, steroid response and response to 
early immunosuppression can be valuable in guiding treatment and transplantation 
decisions. Our data continue to support comprehensive genetic testing in all steroid resistant 
children. In those who test negative, immunosuppression including calcineurin inhibitors +/- 
combination with steroids and other medications should be used with a trial of Rituximab in 
non-responders. Failure indicates the patient is likely to be multi-drug resistant and the 
chance of progression to kidney failure and post-transplant recurrence become high. 
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Figures Legends 
Figure 1: Patient cohort taken from the RaDaR registry current to January 2018. 
Steroid resistant nephrotic syndrome includes patients with primary, presumed and 
secondary steroid resistance. 184 patients were part of the original whole exome 
sequencing cohort that has been previously described by Bierzynska et al 2017.(7)   RaDaR, 
renal rare disease registry. 
 
Figure 2: Response to intensified immunosuppression medications and kidney 
survival in genetic-testing negative patients. Response to all (2a) or first-administered 
(2b) intensified immunosuppression medications. The number of treatments with response 
data available is given in brackets. No data were available for 29/335 treatment episodes 
(first intensified immunosuppression in three patients). Kidney survival (2c) analysed by 
response to first intensified immunosuppression treatment. Numbers in the table represent 
the number of patients at risk for each time point. 
 
Figure 3: Patient stratification and long-term outcomes according to genetic testing 
and response to first intensified immunosuppression. The three stratified patient groups 
are indicated in the grey highlighted boxes.  
 
Figure 4: Response to Rituximab and long-term outcome according to genetic-testing 
and pattern of steroid resistance.  
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Tables 
Table 1: Demographic characteristics of the patient cohort 
 
  Total cohort  Genetic-testing 
negative  
Monogenic 
disease 
Total patients  271 190 81 
Male (%)  137 (51) 98 (52) 39 (48) 
Age at onset (years) 
– number (%) 
0-0.25 36 (13) 8 (4) 28 (35) 
0.25-1 10 (4) 4 (2) 6 (7) 
1-5 129 (47) 107 (56) 22 (27) 
6-12 74 (27) 55 (29) 19 (24) 
13-18 22 (8) 16 (8) 6 (7) 
Median age at onset 
(years) / Interquartile 
range 
 4.8 / 2.4 – 9.3 4.9 / 2.6 – 9.4 3.2 / 1.6 – 8.4 
Family history 
positive / number 
with data available 
(%) 
 39 / 252× (15) 16 / 180 (9) 23 / 72 (32) 
Consanguinity / 
number with data 
available (%) 
 25 / 245 (10) 9 / 175 (5)∞ 16 / 70 (23) 
Ethnicity (% of 
patients where data 
available) 
White 186 (72) 130 (70) 56 (76) 
Asian 18 (7) 15 (8) 3 (4) 
Pakistani 17 (7) 10 (5) 7 (10) 
Black African / 
Caribbean 
13 (5) 10 (5) 3 (4) 
Mixed 8 (3) 8 (4) 0 (0) 
Indian 10 (4) 7 (4) 3 (4) 
Bangladeshi 2 (1) 2 (1) 0 (0) 
Other 6 (2) 4 (2) 2 (3) 
No ethnicity data 
available 
11 4 7 
First biopsy findings 
(% of patients where 
data available) 
FSGS 128 (55) 103 (60) 25 (40) 
Minimal change 
disease 
56 (24) 45 (26) 11 (18) 
Mesangial 
hypercellularity 
16 (7) 9 (5) 7 (11) 
Finnish type 6 (3) 0 (0) 6 (10) 
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Kidney failure 5 (2) 0 (0) 5 (8) 
Diffuse mesangial 
sclerosis 
4 (2) 2 (1) 2 (3) 
Focal global 
glomerulosclerosis 
2 (1) 1 (1) 1 (2) 
Other 17 (7) 11 (6) 6 (10) 
No biopsy data 
available / Not 
biopsied 
37 19 18 
Pattern of steroid 
resistance (%) 
Presumed 54 (20) 15 (8) 39 (48) 
Primary 179 (66) 138 (73) 41 (51) 
Secondary 38 (14) 37 (19) 1 (1) 
    
 
 
Percentages are calculated for column totals. ×Patients were deemed to have a positive 
family history if they had an affected first degree relative, or an affected cousin in a 
consanguineous family. In the genetic-testing negative group this includes seven siblings 
from three families. The monogenic disease group includes 13 siblings from six families. 
∞One patient from a consanguineous family had no mutations identified in known nephrotic 
genes but is under investigation for a novel gene candidate. FSGS, focal segmental 
glomerulosclerosis. 
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Table 2: Number of treatments received and availability of response data 
 
Groups Subgroups Number of 
patients 
Number of 
treatments 
Number of 
patients with 
response 
data 
Number of 
treatments with 
response data 
Total cohort  271 - - - 
Not receiving 
ACEi/ARB or 
intensified 
immunosuppression 
(%) 
Total 
52 (19) - - - 
Reason for no 
ACEi/ARB or 
intensified 
immunosuppression 
Congenital 
nephrotic 
syndrome 
24 - - - 
CKD/kidney failure 
at presentation 
13 - - - 
Syndromic 3 - - - 
Familial 1 - - - 
No medication data 11 - - - 
Total receiving 
treatments (%) 
ACEi/ARB or 
intensified 
immunosuppressio
n 
219 / 271 
(81) 
540 202 / 219 (92) 480 / 540 (89)  
Grouped by patients 
(%) 
ACEi/ARB only 33 / 219 (15) - - - 
Intensified 
immunosuppressio
n only 
86 / 219 (39) - - - 
ACEi/ARB and 
intensified 
immunosuppressio
n 
100 / 219 
(46) 
- - - 
Grouped by 
treatments (%) 
All ACEi/ARB 
133 / 219 
(61) 
160 / 540 
(30) 
112 / 133 (84) 134 / 160 (84) 
All intensified 
immunosuppressio
n 
186 / 219 
(85) 
380 / 540 
(70) 
178 / 186 (96) 346 / 380 (91) 
 
 
ACEi, angiotensin converting enzyme inhibitor; ARB, Angiotensin II receptor blocker; CKD, 
chronic kidney disease.  
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Table 3: Patients with monogenic disease who responded to immunosuppression 
 
Patient Gene Gender Age at 
onset 
(years) 
Resistance 
to steroids 
1st 
biopsy 
CKD 
stage 
Extra-renal 
phenotype 
Length of 
follow-up 
(years) 
Medication 
for which 
there was 
response 
Response 
7656 WT1 M 3 primary 
Diffuse 
mesang
ial 
sclerosi
s 
2 
Denys-
Drash 
syndrome 
1.6 
MMF 
Tacrolimus 
Complete 
Complete 
495 NPHS1 F 2 primary 
Minimal 
change 
disease 
2 No 17.8 MMF Partial 
514 
SMAR
CAL1 
M 7 primary FSGS 1 No 0.4 Ciclosporin Partial 
687 CRB2 F 0 presumed 
Minimal 
change 
disease 
1 No 4.0 Levamisole Partial 
729 NPHS2 M 7 primary Other 2 Asthma 2.8 Tacrolimus Partial 
731 MAGI2 M 0 primary 
Minimal 
change 
disease 
1 
Pyloric 
stenosis, 
Polydactyly, 
Thrombocyt
osis 
11.7 Ciclosporin Partial 
770 
COL4A
3 
F 7 primary FSGS 1 No 2.5 Ciclosporin Partial 
811 WT1 F 3 primary Alports 1 
Chronic 
cough and 
diarrhoea, 
Frasier 
syndrome 
1.1 Tacrolimus Partial 
900 LMX1B F 14 primary FSGS 1 
Delayed 
puberty 
1.1 Tacrolimus Partial 
 
CKD, chronic kidney disease; F, female; FSGS, focal segmental glomerulosclerosis; M, 
male; MMF, mycophenolate mofetil. For correlation of RaDaR numbers with previously 
published ID numbers see supplemental material (Table S3). 
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Table 4: Characteristics and long-term outcomes of genetic-testing negative patients 
stratified by response to first intensified immunosuppression treatment 
 
  Total with 
outcomes 
Complete Partial No P Value 
Number of patients  149 37  32  80   
First-line intensified 
immunosuppression 
treatment 
Ciclosporin 66 (44) 18 17  31  
0.53+ 
Tacrolimus 35 (23) 11  5  19  
Mycophenolate 
Mofetil 
6 (4) 2 0 4  
Cyclophosphamide 32 (21) 4  8 20 
Rituximab 5 (3) 1 1  3  
Levamisole 4 (3) 1 1  2   
Azathioprine 1 (1) 0 0 1  
Age at onset in 
years – number (% 
of column total) 
0-0.25 0 (0) 0 (0) 0 (0) 0 (0) 
0.03^ 
0.25-1 1 (1) 0 (0) 0 (0) 1 (1) 
1-5 89 (60) 26 (70) 24 (75) 39 (49) 
6-12 47 (32) 11 (30) 5 (16) 31 (39) 
13-18 12 (8) 0 (0) 3 (9) 9 (11) 
Pattern of steroid 
resistance 
Presumed steroid 
resistance 
1 (1) 0 (0) 0 (0) 1 (1) 
0.15* 
Primary steroid 
resistance 
117 (79) 26 (70) 24 (75) 67 (84) 
Secondary steroid 
resistance 
31 (21) 11 (30) 8 (25) 12 (15) 
Number (%) who 
developed kidney 
failure 
 41 (28) 1 (3) 5 (16) 35 (44) <0.001& 
Number (%) 
transplanted 
 31 (21) 1 (3) 4 (13) 26 (33) <0.001& 
Number (% of those 
transplanted) with 
post-transplant 
recurrence 
 21/31 (68) 1/1 (100) 1/4 (25) 19/26 (73) 0.30$ 
 
Treatment response data were unavailable for the first intensified immunosuppression 
treatment in three genetic-testing negative patients (all three received ciclosporin). All data 
 31 
 
were complete for age, steroid resistance, kidney failure, transplant and post-transplant 
recurrence. Percentages are calculated for column totals. p values are for the comparison 
between complete, partial and no response. + Chi-squared analysis, 8df. Azathioprine and 
levamisole excluded from analysis. ^ Chi-squared analysis, 4df. “0-0.25”, “0.25-1” and “1-5” 
combined into one group. * Chi-squared analysis, 2df. “Presumed” and “Primary steroid 
resistance” combined into one group.  & Chi-squared analysis, 2df. $ Fishers exact test. 
Complete and partial response combined into one group.  
